Spotlight Innovation Introduces EPISORB

Spotlight Innovation reported that the product EPISORB, developed by its subsidiary Celtic Biotech Iowa, has been registered with the U.S. Food and Drug Administration and has been incorporated into the Pharmacy Benefit Managers (PBM) database referenced by health insurance companies when reimbursing drugs.

According to a media release, the product makes use of the attributes of cardiotoxin as a cell penetrating peptide and is intended for distribution through the compounding pharmacy industry.

Cris Grunewald, President and CEO of Spotlight Innovation, stated, "EPISORB is a transdermal delivery platform, and is a viable alternative to the current topical bases used by the compounding pharmacy industry when preparing analgesic or scar reduction creams. We are excited to be making this product available to the compounding pharmacy industry and to have demonstrated that we can successfully navigate regulatory and distribution requirements."

Dr. Paul Reid, President of Celtic Biotech, said, "This is the first step in our product development program. We intend to maximize the value of our pipeline as we advance our lead products through the required clinical programs."

Spotlight Innovation specializes in identifying, acquiring and incubating companies which have unique intellectual property (IP) in the medical sector.

Celtic Biotech Iowa, a subsidiary of Spotlight Innovation, is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans.